Issue Type: Payer and Supply Chain Economics Favor Higher Cost Drugs
in challenge narrative
-
Biosimilars in Medicare Part D: pricing dynamics and considerations
-
Ethics of Clinical Trials to Evaluate Biosimilars
-
Supply Chain Economics Favor Higher Cost Drugs
-
Who Is Sowing Seeds of Confusion About The QALY?
-
Mortgaging New Treatments Kicks the Can on High Drug Prices
-
60 Minutes: The Rockford File
-
TEDMED Talk: Changing the Drug Pricing Game with Dr. Peter Bach
-
DPL and Collaborators to Publish Drug Pricing Primer Series
-
A Q&A with Peter Bach
-
The Insurance Companies’ Latest Target: Specialty Drugs